{"pages":[{"title":"Categories","date":"2025-04-12T07:27:52.938Z","path":"categories/index.html","text":""},{"title":"About","date":"2025-04-13T12:33:24.388Z","path":"about/index.html","text":"SCP Foundation Personnel File: Agent w163nana SECURITY CLEARANCE: LEVEL 2 (Provisional - Enhanced) CODENAME: w163nana DESIGNATION: Bio-Digital Interface Specialist REAL NAME: Chenxinqi AFFILIATION: Jilin University (Medical Sciences - Active Reserve) CURRENT OPERATIONAL NODE: Site-██, Koto City, Japan (Primary Engagement Zone: Greater Tokyo Metropolitan Anomaly Cluster) SPECIALIZED AUGMENTATIONS &amp; PROFICIENCIES: Integrated Bio-Cognitive Interface (BCI): Demonstrates exceptional synergy between biological neural networks and advanced digital processing units. Capable of real-time data stream integration and analysis, exhibiting accelerated pattern recognition in complex anomalous datasets. Advanced Digital Intrusion &amp; Counter-Infiltration Protocols: Mastery of cutting-edge cybersecurity frameworks and proprietary Foundation counter-intrusion algorithms (e.g., Project Cerberus, GhostNet Protocol). Proven ability to neutralize sophisticated digital threats and secure compromised information architectures. Enhanced Human-Machine Symbiosis: Exhibits a uniquely high degree of adaptability and intuitive control over diverse technological interfaces, including anomalous devices and experimental containment systems. Neural plasticity metrics are significantly above baseline. Linguistic Cryptanalysis &amp; Anomaly Linguistics: Native fluency in Mandarin Chinese, Japanese, and English, augmented by specialized training in deciphering anomalous communication patterns, including non-Euclidean linguistic structures and cognitohazardous vocalizations. Applied Clinical Cognition &amp; Bio-Anomaly Assessment: Leveraging a strong foundation in clinical medicine to analyze and understand the biological and physiological effects of anomalous phenomena on human and other biological systems. Crucial in developing bio-containment protocols and hazard mitigation strategies. PSYCHOLOGICAL &amp; OPERATIONAL PROFILE: Agent w163nana presents as a highly analytical and adaptable individual, demonstrating a unique synthesis of rigorous scientific training and intuitive technological proficiency. Initial psychological evaluations indicate a strong intellectual curiosity bordering on fascination with the anomalous, balanced by a pragmatic and results-oriented approach. The subject’s medical background provides a valuable perspective in understanding the bio-organic implications of SCP objects. Continued monitoring is advised to assess long-term resilience in prolonged exposure to high-threat containment scenarios. OPERATIONAL LOG (Excerpts): ████-██-██: Assisted in the remote analysis of bio-signatures emanating from a temporal distortion event (SCP-████-J), identifying critical physiological markers indicative of temporal stress. ████-██-██: Deployed advanced counter-intrusion measures to neutralize a digital contagion vector originating from a cognitohazardous SCP (SCP-████), preventing widespread informational compromise. ████-██-██: Integral to the bio-containment team for SCP-████, utilizing medical expertise to develop and implement revised quarantine protocols for affected personnel. ████-██-██: Successfully decrypted a series of anomalous audio transmissions linked to a potential reality-bending entity, providing crucial insights into its operational parameters. PERSONAL INSIGHT: “The human body, a universe of intricate systems. Anomalies often twist these systems in unimaginable ways. My medical training provides a foundation, but the digital realm offers the tools to dissect the impossible. We are the scalpel and the code, the biological and the binary, working in concert to understand and contain what should not be. The anomalies challenge our understanding of life itself, and within that challenge lies the potential for profound discovery.” - Agent w163nana END OF PERSONNEL FILE"},{"title":"Tags","date":"2025-04-12T07:27:52.939Z","path":"tags/index.html","text":""}],"posts":[{"title":"python计算多p视频还剩多少时间","date":"2025-05-05T10:11:34.000Z","path":"wiki/python计算多p视频还剩多少时间/","text":"这几天在补有机化学网课，突然想知道还剩多少时间 下载的部分HTML页面源码: 12345678910111213141516171819202122232425262728293031323334353637383940414243444546474849505152535455565758596061626364656667686970&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div data-key=&quot;205742319&quot; class=&quot;simple-base-item video-pod__item normal&quot; data-v-dac4fbd2&gt;&lt;div title=&quot;41第十章醇与酚&quot; class=&quot;title&quot;&gt;&lt;div class=&quot;playing-gif&quot; style=&quot;display:none;&quot;&gt;&lt;/div&gt; &lt;div class=&quot;title-txt&quot;&gt;41第十章醇与酚&lt;/div&gt;&lt;/div&gt; &lt;div class=&quot;stats&quot;&gt;&lt;div class=&quot;stat-item duration&quot;&gt; 23:10 &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div data-key=&quot;205743428&quot; class=&quot;simple-base-item video-pod__item normal&quot; data-v-dac4fbd2&gt;&lt;div title=&quot;42第十章醇与酚第十一章醚&quot; class=&quot;title&quot;&gt;&lt;div class=&quot;playing-gif&quot; style=&quot;display:none;&quot;&gt;&lt;/div&gt; &lt;div class=&quot;title-txt&quot;&gt;42第十章醇与酚第十一章醚&lt;/div&gt;&lt;/div&gt; &lt;div class=&quot;stats&quot;&gt;&lt;div class=&quot;stat-item duration&quot;&gt; 31:09 &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div data-key=&quot;205745493&quot; class=&quot;simple-base-item video-pod__item active normal&quot; data-v-dac4fbd2&gt;&lt;div title=&quot;43第十一章醚&quot; class=&quot;title&quot;&gt;&lt;div class=&quot;playing-gif&quot; style=&quot;display:;&quot;&gt;&lt;/div&gt; &lt;div class=&quot;title-txt&quot;&gt;43第十一章醚&lt;/div&gt;&lt;/div&gt; &lt;div class=&quot;stats&quot;&gt;&lt;div class=&quot;stat-item duration&quot;&gt; 15:05 &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div data-key=&quot;205747106&quot; class=&quot;simple-base-item video-pod__item normal&quot; data-v-dac4fbd2&gt;&lt;div title=&quot;44第十一章醚第十二章醛和酮&quot; class=&quot;title&quot;&gt;&lt;div class=&quot;playing-gif&quot; style=&quot;display:none;&quot;&gt;&lt;/div&gt; &lt;div class=&quot;title-txt&quot;&gt;44第十一章醚第十二章醛和酮&lt;/div&gt;&lt;/div&gt; &lt;div class=&quot;stats&quot;&gt;&lt;div class=&quot;stat-item duration&quot;&gt; 31:30 &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div data-key=&quot;205748659&quot; class=&quot;simple-base-item video-pod__item normal&quot; data-v-dac4fbd2&gt;&lt;div title=&quot;45第十二章醛和酮&quot; class=&quot;title&quot;&gt;&lt;div class=&quot;playing-gif&quot; style=&quot;display:none;&quot;&gt;&lt;/div&gt; &lt;div class=&quot;title-txt&quot;&gt;45第十二章醛和酮&lt;/div&gt;&lt;/div&gt; &lt;div class=&quot;stats&quot;&gt;&lt;div class=&quot;stat-item duration&quot;&gt; 17:22 &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div data-key=&quot;205750225&quot; class=&quot;simple-base-item video-pod__item normal&quot; data-v-dac4fbd2&gt;&lt;div title=&quot;46第十二章醛和酮&quot; class=&quot;title&quot;&gt;&lt;div class=&quot;playing-gif&quot; style=&quot;display:none;&quot;&gt;&lt;/div&gt; &lt;div class=&quot;title-txt&quot;&gt;46第十二章醛和酮&lt;/div&gt;&lt;/div&gt; &lt;div class=&quot;stats&quot;&gt;&lt;div class=&quot;stat-item duration&quot;&gt; 31:10 &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div data-key=&quot;205751433&quot; class=&quot;simple-base-item video-pod__item normal&quot; data-v-dac4fbd2&gt;&lt;div title=&quot;47第十二章醛和酮&quot; class=&quot;title&quot;&gt;&lt;div class=&quot;playing-gif&quot; style=&quot;display:none;&quot;&gt;&lt;/div&gt; &lt;div class=&quot;title-txt&quot;&gt;47第十二章醛和酮&lt;/div&gt;&lt;/div&gt; &lt;div class=&quot;stats&quot;&gt;&lt;div class=&quot;stat-item duration&quot;&gt; 09:39 &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div data-key=&quot;205751974&quot; class=&quot;simple-base-item video-pod__item normal&quot; data-v-dac4fbd2&gt;&lt;div title=&quot;48第十二章醛和酮&quot; class=&quot;title&quot;&gt;&lt;div class=&quot;playing-gif&quot; style=&quot;display:none;&quot;&gt;&lt;/div&gt; &lt;div class=&quot;title-txt&quot;&gt;48第十二章醛和酮&lt;/div&gt;&lt;/div&gt; &lt;div class=&quot;stats&quot;&gt;&lt;div class=&quot;stat-item duration&quot;&gt; 31:51 &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div data-key=&quot;205753132&quot; class=&quot;simple-base-item video-pod__item normal&quot; data-v-dac4fbd2&gt;&lt;div title=&quot;49不饱和醛酮和取代醛酮&quot; class=&quot;title&quot;&gt;&lt;div class=&quot;playing-gif&quot; style=&quot;display:none;&quot;&gt;&lt;/div&gt; &lt;div class=&quot;title-txt&quot;&gt;49不饱和醛酮和取代醛酮&lt;/div&gt;&lt;/div&gt; &lt;div class=&quot;stats&quot;&gt;&lt;div class=&quot;stat-item duration&quot;&gt; 29:04 &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div data-key=&quot;205760119&quot; class=&quot;simple-base-item video-pod__item normal&quot; data-v-dac4fbd2&gt;&lt;div title=&quot;分割线--下册01 50第十四章羧酸&quot; class=&quot;title&quot;&gt;&lt;div class=&quot;playing-gif&quot; style=&quot;display:none;&quot;&gt;&lt;/div&gt; &lt;div class=&quot;title-txt&quot;&gt;分割线--下册01 50第十四章羧酸&lt;/div&gt;&lt;/div&gt; &lt;div class=&quot;stats&quot;&gt;&lt;div class=&quot;stat-item duration&quot;&gt; 26:04 &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div data-key=&quot;205760467&quot; class=&quot;simple-base-item video-pod__item normal&quot; data-v-dac4fbd2&gt;&lt;div title=&quot;02 51第十四章羧酸第十五章羧酸衍生物&quot; class=&quot;title&quot;&gt;&lt;div class=&quot;playing-gif&quot; style=&quot;display:none;&quot;&gt;&lt;/div&gt; &lt;div class=&quot;title-txt&quot;&gt;02 51第十四章羧酸第十五章羧酸衍生物&lt;/div&gt;&lt;/div&gt; &lt;div class=&quot;stats&quot;&gt;&lt;div class=&quot;stat-item duration&quot;&gt; 32:54 &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div data-key=&quot;209815785&quot; class=&quot;simple-base-item video-pod__item normal&quot; data-v-dac4fbd2&gt;&lt;div title=&quot;03 52第十五章羧酸衍生物&quot; class=&quot;title&quot;&gt;&lt;div class=&quot;playing-gif&quot; style=&quot;display:none;&quot;&gt;&lt;/div&gt; &lt;div class=&quot;title-txt&quot;&gt;03 52第十五章羧酸衍生物&lt;/div&gt;&lt;/div&gt; &lt;div class=&quot;stats&quot;&gt;&lt;div class=&quot;stat-item duration&quot;&gt; 32:49 &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div data-key=&quot;209816901&quot; class=&quot;simple-base-item video-pod__item normal&quot; data-v-dac4fbd2&gt;&lt;div title=&quot;04 53第十五章羧酸衍生物&quot; class=&quot;title&quot;&gt;&lt;div class=&quot;playing-gif&quot; style=&quot;display:none;&quot;&gt;&lt;/div&gt; &lt;div class=&quot;title-txt&quot;&gt;04 53第十五章羧酸衍生物&lt;/div&gt;&lt;/div&gt; &lt;div class=&quot;stats&quot;&gt;&lt;div class=&quot;stat-item duration&quot;&gt; 30:24 &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div data-key=&quot;209817367&quot; class=&quot;simple-base-item video-pod__item normal&quot; data-v-dac4fbd2&gt;&lt;div title=&quot;05 54第十五章羧酸衍生物&quot; class=&quot;title&quot;&gt;&lt;div class=&quot;playing-gif&quot; style=&quot;display:none;&quot;&gt;&lt;/div&gt; &lt;div class=&quot;title-txt&quot;&gt;05 54第十五章羧酸衍生物&lt;/div&gt;&lt;/div&gt; &lt;div class=&quot;stats&quot;&gt;&lt;div class=&quot;stat-item duration&quot;&gt; 30:54 &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div data-key=&quot;209817770&quot; class=&quot;simple-base-item video-pod__item normal&quot; data-v-dac4fbd2&gt;&lt;div title=&quot;06 55第十五章羧酸衍生物&quot; class=&quot;title&quot;&gt;&lt;div class=&quot;playing-gif&quot; style=&quot;display:none;&quot;&gt;&lt;/div&gt; &lt;div class=&quot;title-txt&quot;&gt;06 55第十五章羧酸衍生物&lt;/div&gt;&lt;/div&gt; &lt;div class=&quot;stats&quot;&gt;&lt;div class=&quot;stat-item duration&quot;&gt; 30:58 &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div data-key=&quot;209818214&quot; class=&quot;simple-base-item video-pod__item normal&quot; data-v-dac4fbd2&gt;&lt;div title=&quot;07 56第十六章不饱和羧酸和取代羧酸&quot; class=&quot;title&quot;&gt;&lt;div class=&quot;playing-gif&quot; style=&quot;display:none;&quot;&gt;&lt;/div&gt; &lt;div class=&quot;title-txt&quot;&gt;07 56第十六章不饱和羧酸和取代羧酸&lt;/div&gt;&lt;/div&gt; &lt;div class=&quot;stats&quot;&gt;&lt;div class=&quot;stat-item duration&quot;&gt; 33:41 &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div data-key=&quot;209818606&quot; class=&quot;simple-base-item video-pod__item normal&quot; data-v-dac4fbd2&gt;&lt;div title=&quot;08 57第十六章不饱和羧酸和取代羧酸&quot; class=&quot;title&quot;&gt;&lt;div class=&quot;playing-gif&quot; style=&quot;display:none;&quot;&gt;&lt;/div&gt; &lt;div class=&quot;title-txt&quot;&gt;08 57第十六章不饱和羧酸和取代羧酸&lt;/div&gt;&lt;/div&gt; &lt;div class=&quot;stats&quot;&gt;&lt;div class=&quot;stat-item duration&quot;&gt; 29:38 &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div data-key=&quot;209819058&quot; class=&quot;simple-base-item video-pod__item normal&quot; data-v-dac4fbd2&gt;&lt;div title=&quot;09 58第十六章不饱和羧酸和取代羧酸第十七章胺&quot; class=&quot;title&quot;&gt;&lt;div class=&quot;playing-gif&quot; style=&quot;display:none;&quot;&gt;&lt;/div&gt; &lt;div class=&quot;title-txt&quot;&gt;09 58第十六章不饱和羧酸和取代羧酸第十七章胺&lt;/div&gt;&lt;/div&gt; &lt;div class=&quot;stats&quot;&gt;&lt;div class=&quot;stat-item duration&quot;&gt; 30:48 &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div data-key=&quot;209820437&quot; class=&quot;simple-base-item video-pod__item normal&quot; data-v-dac4fbd2&gt;&lt;div title=&quot;10 59第十七章胺&quot; class=&quot;title&quot;&gt;&lt;div class=&quot;playing-gif&quot; style=&quot;display:none;&quot;&gt;&lt;/div&gt; &lt;div class=&quot;title-txt&quot;&gt;10 59第十七章胺&lt;/div&gt;&lt;/div&gt; &lt;div class=&quot;stats&quot;&gt;&lt;div class=&quot;stat-item duration&quot;&gt; 30:38 &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div data-key=&quot;209860755&quot; class=&quot;simple-base-item video-pod__item normal&quot; data-v-dac4fbd2&gt;&lt;div title=&quot;11 60第十七章胺&quot; class=&quot;title&quot;&gt;&lt;div class=&quot;playing-gif&quot; style=&quot;display:none;&quot;&gt;&lt;/div&gt; &lt;div class=&quot;title-txt&quot;&gt;11 60第十七章胺&lt;/div&gt;&lt;/div&gt; &lt;div class=&quot;stats&quot;&gt;&lt;div class=&quot;stat-item duration&quot;&gt; 31:40 &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div data-key=&quot;209861904&quot; class=&quot;simple-base-item video-pod__item normal&quot; data-v-dac4fbd2&gt;&lt;div title=&quot;12 61第十八章其他含氮化合物&quot; class=&quot;title&quot;&gt;&lt;div class=&quot;playing-gif&quot; style=&quot;display:none;&quot;&gt;&lt;/div&gt; &lt;div class=&quot;title-txt&quot;&gt;12 61第十八章其他含氮化合物&lt;/div&gt;&lt;/div&gt; &lt;div class=&quot;stats&quot;&gt;&lt;div class=&quot;stat-item duration&quot;&gt; 31:34 &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div data-key=&quot;209863047&quot; class=&quot;simple-base-item video-pod__item normal&quot; data-v-dac4fbd2&gt;&lt;div title=&quot;13 62第十八章其他含氮化合物&quot; class=&quot;title&quot;&gt;&lt;div class=&quot;playing-gif&quot; style=&quot;display:none;&quot;&gt;&lt;/div&gt; &lt;div class=&quot;title-txt&quot;&gt;13 62第十八章其他含氮化合物&lt;/div&gt;&lt;/div&gt; &lt;div class=&quot;stats&quot;&gt;&lt;div class=&quot;stat-item duration&quot;&gt; 29:29 &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div data-key=&quot;209864212&quot; class=&quot;simple-base-item video-pod__item normal&quot; data-v-dac4fbd2&gt;&lt;div title=&quot;14 63第十八章其他含氮化合物&quot; class=&quot;title&quot;&gt;&lt;div class=&quot;playing-gif&quot; style=&quot;display:none;&quot;&gt;&lt;/div&gt; &lt;div class=&quot;title-txt&quot;&gt;14 63第十八章其他含氮化合物&lt;/div&gt;&lt;/div&gt; &lt;div class=&quot;stats&quot;&gt;&lt;div class=&quot;stat-item duration&quot;&gt; 31:38 &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div data-key=&quot;209865617&quot; class=&quot;simple-base-item video-pod__item normal&quot; data-v-dac4fbd2&gt;&lt;div title=&quot;15 64第十八章其他含氮化合物第二十章杂环化合物&quot; class=&quot;title&quot;&gt;&lt;div class=&quot;playing-gif&quot; style=&quot;display:none;&quot;&gt;&lt;/div&gt; &lt;div class=&quot;title-txt&quot;&gt;15 64第十八章其他含氮化合物第二十章杂环化合物&lt;/div&gt;&lt;/div&gt; &lt;div class=&quot;stats&quot;&gt;&lt;div class=&quot;stat-item duration&quot;&gt; 29:50 &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div data-key=&quot;209866546&quot; class=&quot;simple-base-item video-pod__item normal&quot; data-v-dac4fbd2&gt;&lt;div title=&quot;16 65第二十章杂环化合物&quot; class=&quot;title&quot;&gt;&lt;div class=&quot;playing-gif&quot; style=&quot;display:none;&quot;&gt;&lt;/div&gt; &lt;div class=&quot;title-txt&quot;&gt;16 65第二十章杂环化合物&lt;/div&gt;&lt;/div&gt; &lt;div class=&quot;stats&quot;&gt;&lt;div class=&quot;stat-item duration&quot;&gt; 30:18 &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div data-key=&quot;209867701&quot; class=&quot;simple-base-item video-pod__item normal&quot; data-v-dac4fbd2&gt;&lt;div title=&quot;17 66第二十章杂环化合物&quot; class=&quot;title&quot;&gt;&lt;div class=&quot;playing-gif&quot; style=&quot;display:none;&quot;&gt;&lt;/div&gt; &lt;div class=&quot;title-txt&quot;&gt;17 66第二十章杂环化合物&lt;/div&gt;&lt;/div&gt; &lt;div class=&quot;stats&quot;&gt;&lt;div class=&quot;stat-item duration&quot;&gt; 29:16 &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div data-key=&quot;209868975&quot; class=&quot;simple-base-item video-pod__item normal&quot; data-v-dac4fbd2&gt;&lt;div title=&quot;18 67第二十章杂环化合物第二十一章周环反应&quot; class=&quot;title&quot;&gt;&lt;div class=&quot;playing-gif&quot; style=&quot;display:none;&quot;&gt;&lt;/div&gt; &lt;div class=&quot;title-txt&quot;&gt;18 67第二十章杂环化合物第二十一章周环反应&lt;/div&gt;&lt;/div&gt; &lt;div class=&quot;stats&quot;&gt;&lt;div class=&quot;stat-item duration&quot;&gt; 31:04 &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div data-key=&quot;209870273&quot; class=&quot;simple-base-item video-pod__item normal&quot; data-v-dac4fbd2&gt;&lt;div title=&quot;19 68第二十一章周环反应&quot; class=&quot;title&quot;&gt;&lt;div class=&quot;playing-gif&quot; style=&quot;display:none;&quot;&gt;&lt;/div&gt; &lt;div class=&quot;title-txt&quot;&gt;19 68第二十一章周环反应&lt;/div&gt;&lt;/div&gt; &lt;div class=&quot;stats&quot;&gt;&lt;div class=&quot;stat-item duration&quot;&gt; 29:28 &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div data-key=&quot;209871357&quot; class=&quot;simple-base-item video-pod__item normal&quot; data-v-dac4fbd2&gt;&lt;div title=&quot;20 69第二十一章周环反应&quot; class=&quot;title&quot;&gt;&lt;div class=&quot;playing-gif&quot; style=&quot;display:none;&quot;&gt;&lt;/div&gt; &lt;div class=&quot;title-txt&quot;&gt;20 69第二十一章周环反应&lt;/div&gt;&lt;/div&gt; &lt;div class=&quot;stats&quot;&gt;&lt;div class=&quot;stat-item duration&quot;&gt; 24:08 &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div data-key=&quot;209874488&quot; class=&quot;simple-base-item video-pod__item normal&quot; data-v-dac4fbd2&gt;&lt;div title=&quot;21 70第二十一章周环反应第二十四章碳水化合物&quot; class=&quot;title&quot;&gt;&lt;div class=&quot;playing-gif&quot; style=&quot;display:none;&quot;&gt;&lt;/div&gt; &lt;div class=&quot;title-txt&quot;&gt;21 70第二十一章周环反应第二十四章碳水化合物&lt;/div&gt;&lt;/div&gt; &lt;div class=&quot;stats&quot;&gt;&lt;div class=&quot;stat-item duration&quot;&gt; 24:46 &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div data-key=&quot;209879450&quot; class=&quot;simple-base-item video-pod__item normal&quot; data-v-dac4fbd2&gt;&lt;div title=&quot;22 71第二十四章碳水化合物&quot; class=&quot;title&quot;&gt;&lt;div class=&quot;playing-gif&quot; style=&quot;display:none;&quot;&gt;&lt;/div&gt; &lt;div class=&quot;title-txt&quot;&gt;22 71第二十四章碳水化合物&lt;/div&gt;&lt;/div&gt; &lt;div class=&quot;stats&quot;&gt;&lt;div class=&quot;stat-item duration&quot;&gt; 28:47 &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div data-key=&quot;209881344&quot; class=&quot;simple-base-item video-pod__item normal&quot; data-v-dac4fbd2&gt;&lt;div title=&quot;23 72第二十四章碳水化合物&quot; class=&quot;title&quot;&gt;&lt;div class=&quot;playing-gif&quot; style=&quot;display:none;&quot;&gt;&lt;/div&gt; &lt;div class=&quot;title-txt&quot;&gt;23 72第二十四章碳水化合物&lt;/div&gt;&lt;/div&gt; &lt;div class=&quot;stats&quot;&gt;&lt;div class=&quot;stat-item duration&quot;&gt; 03:58 &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div data-key=&quot;209881703&quot; class=&quot;simple-base-item video-pod__item normal&quot; data-v-dac4fbd2&gt;&lt;div title=&quot;24 73第二十四章碳水化合物&quot; class=&quot;title&quot;&gt;&lt;div class=&quot;playing-gif&quot; style=&quot;display:none;&quot;&gt;&lt;/div&gt; &lt;div class=&quot;title-txt&quot;&gt;24 73第二十四章碳水化合物&lt;/div&gt;&lt;/div&gt; &lt;div class=&quot;stats&quot;&gt;&lt;div class=&quot;stat-item duration&quot;&gt; 29:06 &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div data-key=&quot;209882494&quot; class=&quot;simple-base-item video-pod__item normal&quot; data-v-dac4fbd2&gt;&lt;div title=&quot;25 74第十九章有机合成重排第二十二章元素化合物&quot; class=&quot;title&quot;&gt;&lt;div class=&quot;playing-gif&quot; style=&quot;display:none;&quot;&gt;&lt;/div&gt; &lt;div class=&quot;title-txt&quot;&gt;25 74第十九章有机合成重排第二十二章元素化合物&lt;/div&gt;&lt;/div&gt; &lt;div class=&quot;stats&quot;&gt;&lt;div class=&quot;stat-item duration&quot;&gt; 28:20 &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div data-key=&quot;209883409&quot; class=&quot;simple-base-item video-pod__item normal&quot; data-v-dac4fbd2&gt;&lt;div title=&quot;26 75 第二十二章元素化合物第二十三章金属有机化合物第二十五章蛋白质与核酸第二十六章类脂、萜类化合物、甾族化合物和生物碱&quot; class=&quot;title&quot;&gt;&lt;div class=&quot;playing-gif&quot; style=&quot;display:none;&quot;&gt;&lt;/div&gt; &lt;div class=&quot;title-txt&quot;&gt;26 75 第二十二章元素化合物第二十三章金属有机化合物第二十五章蛋白质与核酸第二十六章类脂、萜类化合物、甾族化合物和生物碱&lt;/div&gt;&lt;/div&gt; &lt;div class=&quot;stats&quot;&gt;&lt;div class=&quot;stat-item duration&quot;&gt; 29:33 python代码： 1234567891011121314151617181920212223242526272829class My_Time: def __init__(self, hours = 0, minutes = 0, seconds = 0): self.hours = hours self.minutes = minutes self.seconds = seconds self._normalize() def _normalize(self): extra_minutes, self.seconds = divmod(self.seconds, 60) self.minutes += extra_minutes extra_hours, self.minutes = divmod(self.minutes, 60) self.hours += extra_hours def __add__(self, other): #初始化函数里会调用_normalize() result = My_Time(self.hours + other.hours, self.minutes + other.minutes, self.seconds + other.seconds) return result def __str__(self): return f&quot;&#123;self.hours:02d&#125;:&#123;self.minutes:02d&#125;:&#123;self.seconds:02d&#125;&quot;if __name__ == &quot;__main__&quot;: accu_time = My_Time(0, 0, 0) with open(&quot;input.in&quot;, &#x27;r&#x27;, encoding = &#x27;utf-8&#x27;) as input: for line in input: line_strp = line.lstrip() if line_strp[0].isdigit(): num = line_strp.split(&#x27;:&#x27;) _minute, _second = int(num[0]), int(num[1]) add_time = My_Time(0, _minute, _second) accu_time += add_time print(accu_time) 实践了一下面向对像编程和自定义运算符 输出的结果令人绝望： 116:11:43 今晚注定是一个不眠之夜，真的不睡了……","tags":[],"categories":[{"name":"技术","slug":"技术","permalink":"https://w163nana.github.io/categories/%E6%8A%80%E6%9C%AF/"}]},{"title":"Python实现开机自动关闭校园网认证程序弹出的“校园网之窗”窗口","date":"2025-05-01T13:02:24.000Z","path":"wiki/Python实现开机自动关闭校园网认证程序弹出的“校园网之窗”窗口/","text":"今天突然想关掉这个“校园网之窗”，正好五一放假了，想在复习补考科目之前折腾折腾。没想到就搞了一个下午（今天11点才起床，五一第一天就莫得了(╯°□°）╯︵ ┻━┻😢） fig1 使用Microsoft的Spy++工具可以监控系统当前具有的窗口有关信息。在列表中找到“校园网之窗”，发现其存在一个Button类型子节点的句柄与利用“拖动搜索工具”找到的关闭按钮的句柄都是00040DB0。 对比其他同级的Botton类实例，发现该节点的不同之处是Size:19*19。所以我利用它来确定目标按钮 之所以要找到按钮发送点击消息，而非对窗口发送关闭消息，是因为后者会导致整个程序关闭（原因不明）。 另提一嘴，某些特殊的按钮不能通过传递系统消息点击，可以利用其他库操作。这里直接用win32gui就可以了。 需要特别注意的是，click_finished这个标记变量需要被子函数访问。所以要用nonlocal在子函数开头声明，否则子函数会将click_finished = True视为声明新变量。因为click_finished不是全局变量，所以不能用global声明。 123456789101112131415161718192021222324252627282930313233343536373839404142434445#操控windows用户界面的接口库import win32gui#提供许多windows用户界面有关的常量import win32con#需要使用time.sleep()方法import time#模拟点击关闭按钮def Mimic_Click_Close(): click_finished = False #该方法的返回值是int，为一级窗口中满足条件的窗口句柄 Window_HWND = win32gui.FindWindow(None, &quot;校园网之窗&quot;) #没有标题为“校园网之窗”的一级窗口，返回值提示“任务失败” if Window_HWND == 0: return False #后续要使用EnumChildWindows()方法枚举目标窗口的所有子窗口，从而找到关闭按钮。这个函数是EnumChildWindows()所需的回调函数，我将在回调函数里实现子窗口的验证和操作。 def enum_child_window_callback(cld_HWND, _): #声明需要使用的上级变量 nonlocal click_finished #该方法返回子窗口句柄对应的类名 cld_class_name = win32gui.GetClassName(cld_HWND) if(cld_class_name != &quot;Button&quot;): return #该方法按顺序返回窗口的四个范围坐标 left, top, right, buttom = win32gui.GetWindowRect(cld_HWND) #注意y轴是向下的，下界&gt;上界 height, width = buttom - top , right - left if((height != 19) or (width != 19)): return win32gui.SendMessage(cld_HWND, win32con.BM_CLICK) click_finished = True return #遍历目标窗口的子窗口，每次均将子节点句柄传递给回调函数 win32gui.EnumChildWindows(Window_HWND, enum_child_window_callback, None) #返回是否成功 return click_finishedif __name__ == &quot;__main__&quot;: while True: time.sleep(0.5) #如果成功则退出程序 if Mimic_Click_Close(): break 最后，由于Windows的task_scheduler的抽风行为，我只能被迫使用startup文件夹来执行脚本 1C:\\Users\\w163n\\SchdTasks&gt; python JLU.PC-Certify-Dialog-Closer.py Win+R输入shell:startup快速打开C:\\Users\\w163n\\AppData\\Roaming\\Microsoft\\Windows\\Start Menu\\Programs\\Startup 在startup里创建这个cmd脚本的快捷方式，在shortcut选项卡中为run选择minimized。 fig4","tags":[],"categories":[{"name":"技术","slug":"技术","permalink":"https://w163nana.github.io/categories/%E6%8A%80%E6%9C%AF/"}]},{"title":"hexo博客的图片存储问题解决","date":"2025-04-30T09:20:09.000Z","path":"wiki/hexo博客的图片存储问题解决/","text":"想了各种方法：图床、网盘API、云服务代理……要么就是不靠谱，要么就是太贵或者技术力不够。最后还是决定直接把图片存在博客的source文件夹中，repo空间满了再说吧…… 刚开始的时候图片总显示不出来，最后发现相对路径只有post能用，换到首页index相对路径就变了。所以最后还是直接在source下面直接新建images文件夹，所有图片都往里面塞吧。有的时候整理得太有条理反而会浪费时间。( •̀ ω •́ )✧","tags":[],"categories":[{"name":"技术","slug":"技术","permalink":"https://w163nana.github.io/categories/%E6%8A%80%E6%9C%AF/"}]},{"title":"简单学习如何建立代理规则","date":"2025-04-30T08:17:31.000Z","path":"wiki/简单学习如何建立代理规则/","text":"昨天折腾了一下多年前接触过的SAO Utils，在设置第三方邮箱客户端时发现无法在系统代理模式下连接163.com的服务器。 img1 于是我想能否使特定程序绕过代理。网上能找到对特定程序禁用代理的方法，但涉及到进程等我不太熟悉的领域，而直接对特定域名(domain)禁用代理、使用直连更为简单（也更为根本得解决了问题，因为说到底就是该域名下的服务期连不上而已） “profile”选项卡👉目标代理的右键选项卡👉“edit rules” “rule type”选择”domain” img2 对于microsoft store，坊间有个笑话：“直连上不了谷歌，代理上不了微软”。我不知道Microsoft Store请求了什么域名，所以只能对该程序下手。还好Clash提供了便捷的方法。 在”Settings”中有”UWP Tools”，编程师傅还是为我这种低技术力网民考虑得很周到啊😁 img3","tags":[],"categories":[{"name":"技术","slug":"技术","permalink":"https://w163nana.github.io/categories/%E6%8A%80%E6%9C%AF/"}]},{"title":"关于“近日来自身对负性事件的思维反刍愈发加重”的现象记录和分析","date":"2025-04-22T06:55:04.000Z","path":"wiki/关于“近日来自身对负性事件的思维反刍愈发加重”的现象记录和分析/","text":"引言 约莫一两天前开始，长春一改四月下旬气候渐暖的趋势，连续下了几天的阴雨。随之同时发生变化的，是我原本风平浪静而暗流涌动的心河。 虽然大多数人不会主动提及，但对负性思维的反刍是普遍存在的心理活动。虽然如此，本人内心正进行的反刍式心理活动已经干扰了正常的生活。 为了了解这一变化的原因并寻求解决方法，我着手对“反刍式思维”相关资料的调研。再此基础上对自身心理活动进行剖析，并写下此文。 现象记录 在上学期中后期的时间里，我一改在那之前的抑郁状态，转而亢奋起来。而在这种过于活跃的亢奋状态下，我很容易得在本班同学面前做出过火的行为而不自知。 其中造成心理阴影面积最大的有两件事。第一件：在朋友圈中发表过于抽象、恶搞、张扬个人生活的照片和视频。第二件：以过于刻意的方式，用这样或那样的、没头没尾的、与对方无关的话题向某女同学F套近乎，导致自己与若干同学的人际关系几乎降至冰点。 现在的情况是：我经常因为害怕自己走进教室时同学的目光而逃避上课，虽然可能只有极少数人会特别注意到我。此外，由于实验课是和女生一起上，这段时间更是对我的煎熬。我时常害怕自己好不容易从电子学院的尴尬人际环境中逃出来后，在新环境下精心打造的正面人设，就这样被自己摧毁、被他人识破，甚至沦为部分人的笑柄。 理论解释 “反刍思维”有许多的理论解释，在这里引用对本人立论有帮助的一条： ……为了验证这个关系，Connor-Smith 和他的同事（2000）对压力反应问卷进行因素分析发现思维闯入与反刍思维都与无意识因素显著高相关。这种无意识因素无需意志努力，在个体意识之外，指导个体应对压力情境。反刍思维可以作为 Nolen-Hoeksema 定义的反刍反应的一个分量表，它是对问题和情绪的一种更有目的的洞察（Lyubomirsy&amp;Nolen-Hoeksema，1995）。反刍思维和思维闯入都与忧虑、思虑特性有关，两者都可以被看作是对压力的非适应性反应。 事件后处理是指受试者对社交失败或尴尬的活动或情况进行广泛而详细的回顾，这些活动或情况使受试者感觉比实际情况更加消极/引发焦虑，并且他们通过广泛回忆类似的偏好性记忆来强化这些回忆。 对于此次出现的恶性思维反刍，其诱因分析如下： 1. 根本原因是担心周末的research_day英语演讲，害怕自己的口语能力得不到认可。 2. 在此基础上，某位同学偶然提到过F同学的英语很好且会上台演讲，当时我的内心有些许不服气。这在我的思维中，将“演讲比赛”和“F同学”建立了连接。 3. 昨晚CBJ对我口语的评价并没有达到我的预期，这更加暴露了我内心的不自信，从而使隐藏的压力增大，最终诱导反刍的发生。 反刍反应如前文所描述的那样不断回想消极事件的前后经过与原委及自己的感受，易增加个体的消极记忆，对事件的消极归因也会使扭曲其对事件的解释，降低解决问题的能力。 显然，造成我目前被动思维反刍状态的根本因素是“当下的压力”而非“过去的事件”。在不自觉的心理活动中，我由于偶然间注意力的闪现，将此压力于“L同学事件”建立了联系。因此，“L同学事件”被我调用为应对压力的保护机制。 可能的应对方法 反刍也许无法避免，就需要在它出现后及时注意到，并进行正确的归因、专注于当下的要事。 对反刍的直接对象进行主动解决或被动远离。 虽然反刍有很多负面效果，但可以乘机借用反刍来总结过去确实存在的失误。过去的失误无法挽回，但是未来要注意展示自我的分寸、与人保持距离、不表露自己的不满、人前尽量表现得热心。特别是，出现亢奋状态时要采取规避措施。 仍然真实存在的社交压力 不可否认的是，当“L同学在场”时，我面对人群社交压力仍然无法避免，除非我主动进行第一次破冰的尝试。（这也有失败的可能性） 在这种情况下就只能尽量原理，在该诱因在场时用各种方法原理、忽视、屏蔽其存在，用“认真做事”的心理满足状态转移对该诱因的注意力。 参考文献 [1]Rumination (psychology) - Wikipedia [2]反刍式思考 - 百度百科 [3]什么是「反刍思维」？（附三个心理学改善方法） - 壹心理","tags":[],"categories":[{"name":"生活","slug":"生活","permalink":"https://w163nana.github.io/categories/%E7%94%9F%E6%B4%BB/"}]},{"title":"python爬取YouTube视频大失败","date":"2025-04-21T14:02:43.000Z","path":"wiki/python爬取YouTube视频大失败/","text":"今天和周涛组队做一个有关多克隆抗体的课堂展示，需要下载一个youtube视频。由于我之前学过一次，便信誓旦旦地把活儿接下来了。结果居然发现我忘记怎么写爬虫了。毕竟我不是专业学这个的，不能持续接触到编程的思维，所以记录就很重要了。我计划利用这个博客记录一些零碎的小收获。 但是今天还没看专业教课书，就先不研究了。这学期四门专业课，加上两门课的补考，时间紧任务重，鸭梨山大啊…… 对了，最近我在玩《魔女的夜宴》。有压力的时候打开来看看美少女，感觉还挺不错的。今天偶然和潘宇浩单独唠了会嗑，感觉这个人还挺不错的诶。（和白容奇比起来，相处得要舒服多了）看来还是我们南方人的下数更合自己口味。","tags":[],"categories":[{"name":"技术","slug":"技术","permalink":"https://w163nana.github.io/categories/%E6%8A%80%E6%9C%AF/"}]},{"title":"《东北芬达哥大战邪恶元首》游戏策划","date":"2025-04-13T12:26:56.000Z","path":"wiki/《东北芬达哥大战邪恶元首》游戏策划/","text":"《东北芬达哥大战邪恶元首》游戏策划方案 一、游戏概述 游戏名称：《东北芬达哥大战邪恶元首》 游戏类型：解谜类剧情游戏，融合电脑操作解谜、RPG 回合制战斗、AVG 分支选择、战棋类战斗玩法 游戏平台：PC 游戏背景：在未来世界，科技高度发达，信息安全成为各国和各大组织争夺的关键。主角受雇于一个表面上维护世界信息安全，实则隐藏着巨大阴谋的神秘组织。在为组织工作的过程中，主角意外知晓了组织背后不可告人的秘密，从而陷入了一场危及生命的逃亡与反击之旅。 二、游戏玩法 （一）第一章：组织内的电脑特工 剧情流程： 在未来的火星历 114 年，人类迎来了和平的时代。此时，世界上仅存的若干政治实体结束了长期的对抗，携手共同开启了对外太空的开发征程。主人公芬达自幼父母双亡，无依无靠，自他有记忆起，便在一个名为 PYRAMID 的组织的安排下成长。这个组织是直属于星际开发联盟的高级别机构，而星际开发联盟是由地球上各个国家共同设立的，具备强大经济和武装能力的联盟，其主要目的是保障外太空资源能够实现和平、安全的开发。 在芬达的认知里，组织对外宣称自己是服务于联盟的特别行动分队，主要负责情报收集和精准打击任务。他作为组织内负责信息作战的工作人员，一直将那些野心勃勃的反动分子视为自己的敌人。 然而，一次偶然的机会改变了一切。有一天，芬达截获到了一条来自敌人高级别的加密信息。信息中提及了一些他看不懂的计划，强烈的好奇心驱使他开始顺藤摸瓜地进行调查。经过一段时间的深入探索，他逐渐了解到对方组织的真实目的 —— 打破目前国际政府组织对太空探索的垄断（限飞政策）。由于芬达长期脱离社会，他并不知道外面的社会阶级分化已经达到了非常严重的程度。在外界，普通人根本没有能力拥有属于自己的飞船，只能到政府和少数个人拥有的飞船上从事极其危险的工作。而这个与组织对立的机构，实际上是由许多地下私飞组织联合建立的武装组织，他们的目的是进行自我防卫，以摆脱这种不公平的现状。 与此同时，芬达还在调查过程中发现了星际开发联盟对其反对者施加触目惊心迫害的证据。他深知这些证据一旦曝光，将会引起轩然大波。但他并未声张，而是继续秘密调查。 随着调查的深入，芬达开始参与到组织的战场资源调度工作中。他通过截获的情报和先进的数据分析系统，为组织提供战场形势的评估，并负责调度战斗力和补给等资源。在这个过程中，他逐渐发现组织的行动往往是为了维护少数人的利益，而那些被视为 “敌人” 的地下私飞组织，实际上是为了争取普通人的生存权利而战。 内心的良知开始觉醒，芬达在资源调度时开始有意无意地偏袒敌方组织。比如，当他得知组织计划对地下私飞组织的某个据点发动攻击时，他会故意延迟战斗力的派遣，或者减少补给的供应。他会通过修改情报数据，让组织误以为敌方据点的防御力量比实际更强，从而放弃攻击计划。又或者在分配补给物资时，他会巧妙地让一些关键物资无法按时送达组织的前线部队，而在某些情况下，甚至会制造一些意外，让部分补给物资 “误送” 到敌方组织的控制区域。 然而，纸终究包不住火。某天，那些被芬达一直隐藏的证据意外泄露了。组织的网络安全团队迅速展开调查，他们通过复杂的网络流量分析技术，追踪到了芬达在调查过程中留下的蛛丝马迹。尽管芬达已经非常小心地隐藏自己的行为，但组织的技术人员还是通过对他访问敏感信息的时间、频率以及与外部网络的异常连接等细节进行分析，错误地将矛头指向了他，认定是他泄露了这些证据。 当组织的武装人员即将破门而入逮捕他时，芬达意识到自己的生命受到了严重威胁，于是他果断地开始了逃亡之旅，游戏剧情也由此进入第二部分。 工作环境：玩家身处组织的机密情报中心，这里摆满了各种先进的电脑设备和监控屏幕。玩家通过操作电脑来完成组织分配的任务。 操作功能解锁 初期：骇入、上报。 后期：指挥。 数值系统： 初期：骇入获取情报点数，上报将其转换成功劳点数，功劳点数用于在每日结束时购买权限和技能。 后期：解锁指挥权限后，开放指挥技能的学习。指挥需要权力点数，权力点数由功劳点数换汇得来。指挥的战斗胜利亦可获得功劳点数。 （二）第二章：逃亡与调查 逃亡背景：主角在真女主的接应下逃亡到反对组织的总部。 剧情流程： 泉此方结局： 职位：情报员 可用装备：S码的所有装备、重量低于1.5kg的进展或远程武器。 技能：获取情报 剧情任务：前往政府军前哨窃取情报。 好感度增加方法：给漫画、手办，陪打游戏。 好结局前提：获取情报“进攻方位”、好感度满。 坏结局触发条件：选择不符合原作角色性格的分支。 牧濑红莉栖结局： 职位：研发员 可用装备：远程武器，轻、中甲。 技能：动作如潮 剧情任务：野外收集装备零件。 好感度增加方法：建设未来机械研究所。 好结局前提：建成未来机械研究所，搜集到足够的零件以制作纳豆沙拉炮。 坏结局触发条件：选择不符合原作角色性格的分支。 黑羽早雪结局： 职位：战士 装备：Black Lotus 技能：鼓舞（蓄力） 剧情任务：抵御一次进攻 好感度增加方法：一开始就是满的 好结局前提：任务完成、好感度满、已解锁另2个结局 坏结局触发条件：选择不符合原作角色性格的分支。 真结局：解锁前3个结局后，玩家在此方和红莉栖的帮助下骇入联盟系统，得知PYRAMID的主管“元首”正在秘密采集鬼畜矿石。他希望利用鬼畜之力完成人类到原神的补完计划。芬达下意识地产生了阻止他的想法，辞别三女主，踏上第三章的征途。他的决心感染了基地的众人，鬼畜战斗组的成员更是坚决的与我们的主角一起出征了。 RPG 回合制战斗 分支选择 AVG （三）第三章：大决战 游戏流程： 第一关：火星前哨。BOSS：红红。 第二关：月球堡垒。BOSS：佟Dark为。 第三关：地球总部。BOSS：元首。 战棋类战斗 战场设定：战斗在棋盘式的地图上进行，每个格子代表一个行动区域。玩家操控自己的部下在棋盘上移动、攻击敌人。 单位类型：有近战、远程、魔法等不同类型的部下，每个单位有不同的移动范围、攻击范围和技能。 剧情推进与分支选择 选择：只有结局一个分支选择：是阻止补完计划还是不阻止。 三、角色系统 主角：拥有独特的电脑操作技能和智慧，在不同阶段有不同的能力表现。在第一阶段是组织的优秀特工，第二阶段成为逃亡者和调查员，第三阶段成为势力领袖。 伙伴角色 第二阶段伙伴：具有RPG角色的等级机制，可以刷级。 第三阶段部下：具有RPG角色的等级机制，可以刷级。同时也有招募机制，每次携带的队友有数量限制。 四、游戏画面与音效 画面风格：生草的灵魂手绘风 + 鬼畜大头贴 音效设计：第一阶段有电脑操作的音效；第二阶段有Galgame背景音乐、战斗音乐、战斗音效等；第三阶段有战棋移动和攻击的音效、战斗音乐。 五、游戏流程 第一阶段剧情推进 第二阶段多周目体验 第三阶段决战 六、开发计划 已新建文件夹","tags":[],"categories":[{"name":"技术","slug":"技术","permalink":"https://w163nana.github.io/categories/%E6%8A%80%E6%9C%AF/"}]},{"title":"Nano Ultrasound Contrast Agent for Synergistic Chemo-photothermal Therapy and Enhanced Immunotherapy Against Liver Cancer and Metastasis","date":"2025-04-12T07:09:37.000Z","path":"wiki/Nano-Ultrasound-Contrast-Agent-for-Synergistic-Chemo-photothermal-Therapy-and-Enhanced-Immunotherapy-Against-Liver-Cancer-and-Metastasis/","text":"Introduction Liver cancer is a major global health concern, with approximately 1 million new patients diagnosed each year. [cite: 502, 63, 64] A significant number of these patients are diagnosed at an advanced stage, making them ineligible for surgical treatments. [cite: 502, 63, 64] In such cases, traditional treatment methods like thermal ablation, chemotherapy, and immunotherapy often yield unsatisfactory results due to the complexity and heterogeneity of the tumor. [cite: 503, 65] The propensity of liver cancer to metastasize adds another layer of difficulty to treatment and severely impacts patient prognosis. [cite: 504, 66] Consequently, there’s a critical need for research focused on developing effective combination therapies that can enhance treatment efficacy and reduce metastasis. [cite: 505, 67] Combination therapy, which strategically employs multiple treatment modalities, has emerged as a promising approach to improve outcomes. [cite: 493, 54] By targeting various pathways and modulating the tumor’s immune microenvironment, combination therapy can more effectively disrupt cancer progression. [cite: 493, 54] Among the innovative tools being explored for liver cancer treatment, nanodrug delivery systems hold significant promise. [cite: 494, 55] These systems offer the potential for targeted drug delivery, reduced toxicity, and enhanced therapeutic efficacy. [cite: 494, 55] This study introduces a novel nano ultrasound contrast agent, abbreviated as ATO/PFH NPs@Au-cRGD, designed to integrate diagnosis and treatment for efficient ultrasound imaging and liver cancer therapy. [cite: 495, 56] The core components of this system are: Arsenic trioxide (ATO): A therapeutic agent known to induce ferroptosis, a distinct form of programmed cell death, in tumor cells. [cite: 495, 56, 512, 74] Perfluorohexane (PFH): A substance used to enhance the ultrasound echo signal. [cite: 495, 56, 528, 94] Gold nanoparticles (AuNPs): Act as a carrier for ATO and PFH and facilitate photothermal therapy (PTT). [cite: 495, 56, 508, 70] cRGD peptide: A targeting ligand that enhances the delivery of the nano-agent to liver cancer cells. [cite: 495, 56, 529, 95] The research demonstrates that this nanodrug delivery system promotes the release of tumor-associated antigens (TAAs) through ATO-induced ferroptosis and photothermal-induced immunogenic cell death. [cite: 496, 57] This process enhances the synergistic effects of ATO and photothermal therapy in human Huh7 and mouse Hepa1-6 cells. [cite: 496, 57] A key finding of the study is the system’s ability to activate the antitumor immune response and promote macrophage M1 polarization within the tumor microenvironment. [cite: 497, 58] Notably, these beneficial effects were observed with low side effects in both subcutaneous and orthotopic liver cancer models. [cite: 497, 58] Furthermore, the research reveals that combining the nanodrug delivery system with anti-programmed death-ligand 1 (PD-L1) immunotherapy inhibits tumor metastasis and establishes long-term immunological memory in orthotopic liver cancer. [cite: 498, 59] This combination not only enhances antitumor therapy and suppresses lung metastasis but also enables visual assessment of therapeutic efficacy. [cite: 499, 60] These capabilities highlight the significant potential of this nano-agent for clinical applications in treating liver cancer. [cite: 499, 60] Detailed Discussion of Key Components and Mechanisms Arsenic Trioxide (ATO) and Ferroptosis Arsenic trioxide (ATO) has shown considerable clinical benefits in the palliative treatment of unresectable primary liver cancer. [cite: 518, 83] However, its clinical application is limited by high systemic toxicity, rapid renal elimination of ATO, and low delivery efficiency to liver cancer cells, which greatly reduce the therapeutic efficacy and lead to severe systemic toxicity. [cite: 519, 84, 520, 85, 86] To address these limitations, nanotechnology-based nanodrug delivery systems offer a promising solution. [cite: 521, 87] These systems can significantly improve the efficacy of ATO, reduce its toxicity, and achieve targeted drug delivery in liver cancer. [cite: 521, 87] Since ATO has a strong affinity for sulfhydryl groups (SH) in proteins, it can theoretically inactivate a variety of enzymes containing SH, such as glutathione (GSH). [cite: 521, 87] Glutathione (GSH) could assist glutathione peroxidase 4 (GPX4) in reducing toxic lipid peroxides (LPOs) to nontoxic hydroxy compound (LOH) to prevent LPO-mediated damage to cell membrane structure and function. [cite: 522, 88] The depletion of GSH could result in the inhibition of GPX4 activity and a corresponding increase in intracellular LPO levels, ultimately leading to ferroptosis. [cite: 522, 88] Therefore, ATO may induce ferroptosis through GSH depletion and GPX4 inactivation. [cite: 522, 88] Moreover, the ferroptosis-induced release of TAAs from dying cancer cells could further enhance the immune response. [cite: 522, 88] Photothermal Therapy (PTT) and Gold Nanoparticles (AuNPs) Photothermal therapy (PTT) is an anticancer strategy that offers precise targeting of tumors with minimal damage to surrounding healthy tissues. [cite: 506, 68, 507, 69] Gold nanoparticles (AuNPs) are well-suited for PTT applications due to their good biocompatibility and excellent optical properties. [cite: 508, 70] When AuNPs are exposed to near-infrared (NIR) light, they efficiently absorb the light energy and convert it into heat. [cite: 509, 71] This photothermal effect can damage tumor tissues or release therapeutic molecules, such as tumor-associated antigens (TAAs). [cite: 509, 71, 516, 80] However, the therapeutic effect of AuNPs alone may be limited. [cite: 516, 80, 517, 81] The synergistic effect of combined chemo-PTT may be a promising strategy for improving PTT efficacy. [cite: 517, 81, 506, 68] Ultrasound-Targeted Microbubble Destruction (UTMD) Ultrasound-targeted microbubble destruction (UTMD) can be exploited to change the structures of cells to facilitate the targeted release of nanodrugs into tumor cells, which could improve the efficacy of tumor treatment and prevent the systemic toxicity of antitumor drugs. [cite: 525, 91] The nanoparticles (NPs) accumulate in tumor tissues through the enhanced permeability and retention effect (EPR) and targeting effect. [cite: 526, 92] Then, UTMD can increase the permeability of the cell membrane through the cavitation effect so that the drugs loaded in NPs are more easily released and taken up. [cite: 527, 93] Moreover, NPs can also load imaging agents for visualizing therapy, such as perfluorohexane (PFH). [cite: 528, 94] The Role of cRGD Peptide In this study, the nanodrug delivery system is conjugated with the cyclic arginylglycylaspartic acid peptide (cRGD). [cite: 529, 95, 530, 96] Since ανβ3 integrin-specific ligands are overexpressed in liver cancer and neovascularization cells, a cyclic arginylglycylaspartic acid peptide (cRGD) can be bound to AuNPs via gold-sulfur bonds for targeted liver cancer therapy. [cite: 530, 96, 531, 97, 532, 98] Perfluorohexane (PFH) and Ultrasound Imaging Perfluorohexane (PFH) is a stable, safe, and nontoxic liquid that can undergo a phase transition and enhance the ultrasound echo signal under ultrasonic stimulation and photothermal effects. [cite: 528, 94, 529, 95, 535, 100] This property makes it valuable for ultrasound imaging, allowing for the visualization of the nano-agent’s distribution and therapeutic effects. [cite: 535, 100, 536, 101] Mechanism of Action of the Nano-Agent The nano ultrasound contrast agent, ATO/PFH NPs@Au-cRGD, functions through a multifaceted mechanism: Induction of Ferroptosis: ATO induces ferroptosis in tumor cells through GSH depletion and increased GPX4. [cite: 512, 74] The increased ROS can also directly kill tumor cells, thereby enhancing the synergistic effect. [cite: 512, 74, 513, 75, 513, 76, 514, 77] Photothermal Effect: AuNPs generate heat under NIR laser irradiation, contributing to tumor cell death. [cite: 506, 68, 507, 69, 508, 70, 509, 71] Immune Modulation: Ferroptosis and photothermal effects promote the maturation of dendritic cells (DCs) and macrophage M1 polarization in the tumor microenvironment (TME). [cite: 514, 78] This activation of the immune system triggers an adaptive T-cell response, leading to the generation of cytotoxic T lymphocytes that can attack tumor cells. [cite: 514, 78] Enhanced Immunotherapy: The anti-PD-L1 mAb further promotes the anti-tumor effect of cytotoxic T lymphocytes by blocking the PD-1/PD-L1 axis, which enables synergistic treatment of orthotopic liver cancer, enhances the immune response, and reduces lung metastasis. [cite: 515, 79] In essence, this nanodrug delivery system could realize visual imaging, enable synergistic treatment of liver cancer, enhance the immune response and influence the phenotypes of macrophages in TME, thereby achieving enhanced liver tumor therapy, reducing metastasis, and enabling visual assessment of therapeutic efficacy. [cite: 536, 101, 537, 102] Synthesis and Characterization of the Nano-Agent The ATO/PFH NPs@Au-cRGD nano-agent is synthesized using a filming-rehydration method with minor modifications to established protocols. [cite: 538, 103, 539, 104] Lipid Membranes: DSPE-PEG_{2K} , a biocompatible, biodegradable, and amphiphilic material, is used as a backbone to construct aptamer-functionalized core-shell nanoparticles. [cite: 539, 104, 540, 105, 541, 106] DSPE-PEG_{2k}-SI, DOTAP, DPPC, and cholesterol formed lipid membranes to load ATO and PFH, and to synthesize ATO/PFH NPs. [cite: 541, 106, 542, 107] Gold Nanoshells: AuNPs were deposited onto the surface of liposomes via reduction of chloroauric acid (HAuCl_{4}) following a previously reported method. [cite: 542, 107, 533, 98, 534, 99, 543, 108] Then, RGD-SH binds to the gold shell through SH bonds. [cite: 542, 107, 533, 98, 534, 99, 543, 108] cRGD Conjugation: cRGD-SH is then bound to the gold shell via SH bonds to achieve targeted delivery. [cite: 542, 107, 533, 98, 534, 99, 543, 108] The successful synthesis of the nano-agent is confirmed through various characterization techniques: Transmission Electron Microscopy (TEM): TEM confirmed the deposition of AuNPs on the liposome surface. [cite: 543, 108, 544, 109] Hydrodynamic Diameter and Zeta Potential: The hydrodynamic diameter was 121 ± 5 nm, and the Zeta potential was 10.47 ± 1.20 mV in aqueous solution. [cite: 544, 109, 545, 110, 546, 111] Size Distribution: The size range of the ATO/PFH NPs@Au-cRGD was ≈100-150 nm. [cite: 545, 110, 546, 111] Stability Analysis: After storage at 4, 25, and 37°C in phosphate-buffered saline (PBS) and serum (5%, pH 7.4) for 7 days, there was no obvious change in particle size and Zeta potential, indicating good stability of the synthesized nanoparticles. [cite: 546, 111, 547, 112] UV-Vis Spectra: UV-vis spectra showed that ATO/PFH NPs@Au-cRGD had a characteristic plasmonic coupling (between the AuNPs) absorption peak at 760 nm, while no resonance peak at the near-infrared wavelengths was detected in non-coated liposomes. [cite: 547, 112, 548, 113, 549, 114] Energy-Dispersive X-ray Spectroscopy (EDS): EDS analysis further confirms the formation of a gold shell surrounding the liposome core. [cite: 547, 112, 548, 113, 549, 114] In Vitro Drug Release and Ultrasound Imaging The study also investigates the controlled release ability of ATO from the nanodrug delivery system and its ultrasound imaging capabilities. [cite: 549, 115, 550, 116] Drug Release: The drug release characteristics of ATO were detected at pH 7.4 and 6.5 (pH 6.5 was used to simulate the slightly acidic TME). [cite: 549, 115, 550, 116, 551, 117, 552, 118] Compared to the fast release of free ATO (≈92% in 24 h), ATO NPs-cRGD showed significant sustained release. [cite: 551, 117, 552, 118] ATO can be effectively released with the aid of an ultrasound therapeutic apparatus and low acidity TME (PH 6.5). [cite: 553, 120, 554, 121] The acoustic cavitation effect generated by UTMD is a process of vibration, expansion, contraction, and rupture of microbubbles, which lead to the destruction of the nanocarrier and the release of the drug encapsulated in the nanoparticles, thus promoting the selective release at the tumor site. [cite: 555, 122] Ultrasound Imaging: In vivo and in vitro imaging experiments were carried out with saline as a negative control and SonoVue contrast agent as a positive control to evaluate the ultrasound imaging ability of ATO/PFH NPs@Au-cRGD. [cite: 556, 123, 557, 124, 558, 125] The contrast-enhanced images of SonoVue and ATO/PFH NPs@Au-CRGD were significantly enhanced in vitro after ultrasound exposure, and similar results were detected in in vivo imaging. [cite: 556, 123, 557, 124, 558, 125] Compared to commercial ultrasound contrast agents, the ATO/PFH NPS@Au-cRGD exhibited similar ultrasound imaging effects in tumors, clearly showing contrast enhancement in contrast mode, which could assess the dynamic blood perfusion of tumors visually, thereby realizing precise molecular imaging during treatment. [cite: 560, 127] Photothermal Properties: The photothermal properties of the ATO/PFH NPs@Au-cRGD were investigated using a 760 nm laser to irradiate PBS, AuNPs, ATO, and ATO NPs@Au-cRGD. [cite: 561, 128, 562, 129] After 4 min of irradiation, the maximum temperatures of the AuNPs and ATO NPs@Au-cRGD were 54.2 ± 0.6°C and 48.7 ± 0.7°C, respectively. References Qiu Y, Wu Z, Chen Y, Liao J, Zhang Q, Wang Q, Duan Y, Gong K, Chen S, Wang L, Fan P, Duan Y, Wang W, Dong Y. Nano Ultrasound Contrast Agent for Synergistic Chemo-photothermal Therapy and Enhanced Immunotherapy Against Liver Cancer and Metastasis. Adv Sci (Weinh). 2023 Jul;10(21):e2300878. doi: 10.1002/advs.202300878. Epub 2023 May 10. PMID: 37162268; PMCID: PMC10375134.","tags":[],"categories":[{"name":"知识","slug":"知识","permalink":"https://w163nana.github.io/categories/%E7%9F%A5%E8%AF%86/"}]}],"categories":[{"name":"技术","slug":"技术","permalink":"https://w163nana.github.io/categories/%E6%8A%80%E6%9C%AF/"},{"name":"生活","slug":"生活","permalink":"https://w163nana.github.io/categories/%E7%94%9F%E6%B4%BB/"},{"name":"知识","slug":"知识","permalink":"https://w163nana.github.io/categories/%E7%9F%A5%E8%AF%86/"}],"tags":[]}